Objective Adoptive immunotherapy is an active approach, but efficacy is limited in the clinic for most solid tumor. We hypothesized that there are three factors might lead to improved clinical outcome in the patients with gastric cancer that include: 1) the combination of multiple immune cells, 2) more effector cells reaching at the site of the tumor by infusion in peritoneal cavity, 3) performing of immunotherapy as soon as possible after operation.

Patients & Methods 51 gastric cancer patients (stage III-IV 42/51) who underwent operation from September 2005 to March 2008 were retrospectively analyzed. Data were censored in 39 months (January 2009),Group A patients (n=22) received a course of immunotherapy which included autologous tumor lysate-pulsed dendritic cell (DC) via intradermic injection, cytokine induced killer cells (CIK) by iv, as well as DC-CIK by intraperitoneal injection in 11-14 days after operation, then a standard chemotherapy (18/22) and immunotherapy again. Group B patients (n=29) only received postoperative chemotherapy. Overall survival (OS) and disease-free survival (DFS) were calculated by the Kaplan-Meier method.

Results In total, 24 patients died, giving a median survival time of 25 months. The estimated 2-year OS and DFS of group A were 63.6% and 67.3%, while that of group B were 25.2% and 33.2%, respectively. Both of the estimated 3-year OS and DFS were significantly superior in group A (log-rank test, P<0.01).

Conclusions Early post-operative adoptive multiple-cellular immunotherapy with infusion in peritoneal cavity significantly improved overall survival and disease-free survival in gastric cancer patients.

Key words gastric cancer; early; postoperative; adoptive cellular immunotherapy

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1930.